Pancreatic Cancer Research

ResearcherIRCCS Ospedale San RaffaeleNo recent work listed

Valentina Pasquale

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1250-0825; OpenAlex author ID A5060976896. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
15
Papers, trials and grants by year

2016: 3 papers · 2017: 2 papers · 2018: 3 papers · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper

Papers 10

  1. A Comprehensive Characterization of Stemness in Cell Lines and Primary Cells of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/ijms231810663↗
  2. Glucose metabolism during tumorigenesis in the genetic mouse model of pancreatic cancer. Co-author DOI 10.1007/s00592-019-01335-4↗
  3. Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected pancreatic cancer: A correlation with c… Co-author DOI 10.1016/j.pan.2018.09.006↗
  4. Four-class tumor staging for early diagnosis and monitoring of murine pancreatic cancer using magnetic resonance and ultrasound. First author DOI 10.1093/carcin/bgy094↗
  5. No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay. Co-author DOI 10.3233/cbm-181218↗
  6. A preoperative score to predict early death after pancreatic cancer resection. Co-author DOI 10.1016/j.dld.2017.06.012↗
  7. Modeling the Iatrogenic Pancreatic Cancer Risk After Islet Autotransplantation in Mouse. First author DOI 10.1111/ajt.14360↗
  8. Diabetes associated with pancreatic ductal adenocarcinoma is just diabetes: Results of a prospective observational study in surgical patients. Co-author DOI 10.1016/j.pan.2016.08.005↗
  9. (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial. Co-author DOI 10.1158/1078-0432.ccr-15-1722↗
  10. Effect of Diabetes on Survival after Resection of Pancreatic Adenocarcinoma. A Prospective, Observational Study. Co-author DOI 10.1371/journal.pone.0166008↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Erica Dugnani · 10 shared papers, 2016–2022 · strength 0.74
  2. Lorenzo Piemonti · 10 shared papers, 2016–2022 · strength 0.74
  3. Gianpaolo Balzano · 8 shared papers, 2016–2022 · strength 0.58
  4. Michele Reni · 7 shared papers, 2016–2022 · strength 0.52
  5. Daniela Liberati · 8 shared papers, 2016–2019 · strength 0.52
  6. Claudio Doglioni · 7 shared papers, 2016–2018 · strength 0.41
  7. Massimo Falconi · 6 shared papers, 2016–2018 · strength 0.35
  8. Vito Lampasona · 3 shared papers, 2016–2018 · strength 0.20
  9. Benedetta Ferrara · 1 shared paper, 2022 · strength 0.16
  10. Francesco De Sanctis · 1 shared paper, 2018 · strength 0.07
  11. Massimo Venturini · 1 shared paper, 2018 · strength 0.07
  12. Giulio Belfiori · 1 shared paper, 2017 · strength 0.06
  13. Stefano Crippa · 1 shared paper, 2017 · strength 0.06
  14. Stefano Cereda · 1 shared paper, 2016 · strength 0.05
  15. Carmen Belli · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.